Related by context. All words. (Click for frequent words.) 73 eTag assays 71 VeraTag assays 70 HERmark assay 69 VeraTag 67 PCA3 66 miRview mets 65 CCX# 65 VeraTag technology 65 VeriStrat 64 Oncotype DX colon cancer 64 predictive biomarker 64 PROLARIS 64 Cervista HPV HR 64 nonclinical studies 64 Symadex 64 Azedra ™ 64 KRAS mutation 64 Azedra 64 Breast Cancer Assay 63 Epigenomics proprietary 63 MOZOBIL 63 CoFactor 63 Oncotype DX breast cancer 63 APOPTONE 63 RIGScan CR 63 Trofile 63 predictive biomarkers 63 LungExpress Dx TM 63 Recurrence Score 63 FDG PET 63 miRview squamous 63 PCA3 test 62 enzastaurin 62 Fludara ® 62 CTAP# Capsules 62 Mammostrat 62 Trofex 62 ENMD # 62 CD# CEA 62 trastuzumab DM1 T DM1 62 CellPort Technologies 62 HER2 expression 62 QTinno TM 62 MAGE A3 ASCI 62 Allovectin 7 R 62 PITX2 62 OXi# 62 APTIMA HPV assay 62 APTIMA HPV 62 Telatinib 62 Anticalin ® 62 HER2 positive metastatic breast 62 tubulin inhibitor 62 prognostic markers 62 COLD PCR 62 alvespimycin 62 BCX# 62 preclinically 62 INCB# [001] 61 Oncotype DX 61 pharmacodynamic PD 61 neratinib 61 molecular biomarkers 61 multigene expression test 61 p# biomarker 61 Exelixis compounds 61 ResponseDX Lung TM 61 qRT PCR 61 SERMs 61 SNALP 61 DAVANAT 61 Panzem R NCD 61 MassARRAY platform 61 XmAb# 61 ADVEXIN 61 trastuzumab DM1 61 PreGen Plus 61 K ras mutations 61 molecular biomarker 61 miRview ™ squamous 61 NADiA 61 Xanafide 61 anti CD# antibodies 61 biomarker 61 viral kinetics 61 MammaPrint 61 FGFR 61 forodesine 61 HGS ETR1 61 ALTROPANE 61 vidofludimus 61 antiangiogenic agent 61 ALN VSP 61 huC# DM4 61 lintuzumab 61 ALN TTR 61 Previstage TM GCC 61 PSMA ADC 61 pharmacogenetic test 61 MAbs 61 miRview meso 61 MET amplification 60 YONDELIS 60 FOLOTYN 60 Solazed TM 60 CYT# potent vascular disrupting 60 pertuzumab 60 OvaRex R 60 OVA1 60 quantitative gene expression 60 diagnostic prognostic 60 Azedra TM 60 mertansine 60 splice variants 60 BrachySil TM 60 RECIST Response Evaluation Criteria 60 pharmacogenetic testing 60 #F FDG PET 60 NADiA ProsVue 60 PEG SN# 60 MGd 60 HIFU therapy 60 p# biomarkers 60 immunohistochemical 60 Dyax phage display 60 delafloxacin 60 ALN PCS 60 oral gallium 60 serum biomarkers 60 Response Evaluation Criteria 60 CR# vcMMAE 60 Traficet EN 60 PANVAC VF 60 DNA methylation biomarkers 60 ongoing Phase IIIb 60 Corus CAD 60 adecatumumab 60 GAMMAGARD 60 K RAS 60 QTinno 60 pharmacogenetic tests 60 Vitaxin 60 BRACAnalysis 60 molecular profiling 60 Neuradiab 60 EpCAM 60 MyVax R 60 pharmacogenetic 60 Septin 9 60 RRM1 60 vorinostat 60 MammaPrint R 60 Phase #/#a trial 60 companion diagnostics 60 differentiate squamous 60 KRAS mutation status 59 Septin9 59 NPM1 59 OMAPRO 59 Oncotype 59 genomic biomarkers 59 MEK inhibitors 59 methylation markers 59 OnDose TM 59 nomograms 59 miRview TM mets 59 Trofex TM 59 rBChE 59 oncolytic virus therapies 59 KRAS mutations 59 DOS# 59 GFT# 59 EGFR TKIs 59 PROSTASCINT R 59 LungExpress Dx 59 ImmuKnow R 59 Xelox 59 epithelial tumors 59 Bezielle 59 CINQUIL 59 Ceflatonin 59 gefitinib Iressa 59 miRview ™ mets 59 NMP# 59 HuMax 59 HER3 59 PCA3 assay 59 bardoxolone 59 Chemophase 59 EGFR mutations 59 thymidylate synthase TS 59 cancer immunotherapies 59 OncotypeDX 59 KRAS variant 59 OnDose 59 registrational trial 59 erlotinib Tarceva ® 59 ImmuKnow 59 PS# [001] 59 #D#C# 59 CCR9 antagonist 59 genetic biomarkers 59 SmartChip System 59 Targretin 59 AEG# 59 novel VDA molecule 59 NovaBay Aganocide compounds 59 pralatrexate 59 CLORETAZINE TM VNP#M 59 ANYARA 59 UsiRNAs 59 Phase Ib study 59 GRNCM1 59 delta isoform 59 Solorel TM 59 therapeutic monoclonal antibody 59 microRNA biomarkers 59 IMA# 59 INTERCEPT platelets 59 Tarceva TM 59 Thalomid ® 59 Insegia 59 Oncotype DX Recurrence Score 59 isoform selective 59 ARCHITECT HIV 59 Capesaris 59 PXD# 59 florbetaben 59 PGxPredict tests 59 taxane therapy 59 vaccines oncolytic virus 59 cleavable linker 59 neoadjuvant chemotherapy 59 HspE7 58 Archexin 58 depsipeptide 58 biodistribution 58 VerifyNow 58 PITX2 methylation 58 TREANDA 58 Anticalin R 58 vismodegib 58 Zevalin consolidation 58 epigenetic therapies 58 ganetespib 58 EOquin 58 EGFR HER2 58 ELACYT 58 ResponseDX 58 ThermoDox ® clinical 58 T#I [002] 58 PLX cells 58 SAR# [004] 58 elotuzumab 58 Zemiva TM 58 JAK inhibitors 58 FullTerm 58 HAAH 58 eniluracil 58 STRIDE PD 58 antiangiogenic agents 58 KRAS status 58 Ag Ab Combo 58 tanespimycin 58 pharmacodynamic biomarkers 58 Clusterin 58 bioinformatic approaches 58 KRAS mutations occur 58 UroVysion 58 Virulizin ® 58 tumor subtypes 58 vivo fluorescence imaging 58 NuroPro R 58 TRISENOX 58 OncoVEX GM CSF 58 Panzem R 58 cMET 58 anti angiogenic drugs 58 favorable pharmacokinetic profile 58 xTAG RVP 58 preclinical efficacy 58 RAV# 58 Prognostic 58 IMGN# 58 DsiRNA 58 Cystatin C 58 Oncotype DX ® 58 HuMax EGFr 58 oral picoplatin 58 Activity Assay 58 PD2i Analyzer 58 VKORC1 58 OncoVEX 58 mRCC 58 pharmacodynamic properties 58 specific antigen PSA 58 Amrubicin 58 Biomerk Tumorgrafts 58 cytotoxic agents 58 fosbretabulin 58 KNS # 58 deforolimus 58 JAK1 58 IGF IR 58 co receptor tropism 58 Multiferon R 58 HGS ETR2 58 IRX 2 58 immunomodulation 58 Lenocta 58 LEUKINE 58 surrogate endpoint 58 GLP toxicology studies 58 PD2i ® 58 IL# PE#QQR 58 ZEVALIN ® 58 antiangiogenesis therapies 58 Solid Tumors 58 QuadraSphere 58 sDNA 58 trastuzumab Herceptin 58 Allovectin 7 ® 58 mSEPT9 58 VitiGam 58 pharmacodynamic effects 58 breast cancer subtypes 58 GeneSightRx 58 EUS FNA 58 Pertuzumab 58 pharmacogenomic tests 58 EGFR HER 58 histone deacetylase inhibitor 58 immunotherapeutic approaches 58 CA9 SCAN 58 BREVAGen ™ 58 HER2 58 molecular subtypes 58 NCCN guidelines 58 oral ridaforolimus 58 Lp PLA2 58 Onalta 57 NuroPro ® 57 antisense oligonucleotides 57 dacetuzumab 57 endocrine therapies 57 pain palliation 57 SNALP technology 57 GRAVITAS trial 57 bafetinib 57 secretory phospholipase A2 sPLA2 57 pCR 57 PGxPredict 57 Onconase 57 thymalfasin 57 investigational immunotherapy 57 MGCD# [001] 57 Sphingomab 57 Hexvix 57 BACcel ™ system 57 NMP# BladderChek Test 57 UGT#A# 57 MTWA testing 57 non squamous NSCLC 57 CD# antibody [001] 57 GVAX Pancreas Vaccine 57 pharmacodynamic markers 57 HemeScan test 57 Hsp# inhibition 57 Degarelix 57 deCODE AF TM 57 Agilent microarrays 57 systemic immunosuppressive drugs 57 recurrent NSCLC 57 biostatistical analysis 57 zanolimumab 57 HER2 overexpression 57 MAGE A3 57 RNAi therapeutic targeting 57 Onalta ™ 57 biomarker assays 57 Tyrima 57 Clolar ® 57 EDEMA3 trial 57 Personalized Immunotherapy 57 EFAPROXYN 57 SNP genotyping 57 WavSTAT 57 Pralatrexate 57 ALN TTR# 57 rALLy trial 57 Angiolix 57 TOCOSOL Paclitaxel 57 MAXY G# 57 kidney urologic 57 ChemoFx 57 antiangiogenic activity 57 ChIP chip 57 Rigel R# 57 immunohistochemical staining 57 Campath alemtuzumab 57 PLAC Test 57 oral Xeloda 57 prostate cancer CaP 57 ImmuKnow assay 57 sorafenib tablets 57 HER-2/neu 57 Hedgehog inhibitor 57 NEUVENGE 57 metabolomic profiling 57 Curaxin CBLC# 57 Campath ® 57 BioMAP 57 pancreatic prostate 57 Nexavar ® 57 CORT # 57 CellSearch ™ 57 sirtuin modulators 57 DiLA2 57 immunohistochemical analysis 57 castration resistant prostate cancer 57 Outpatient Setting 57 TLE3 57 F FDG PET 57 xenograft models 57 OPAXIO 57 talactoferrin 57 lumiliximab 57 Tamibarotene 57 immunohistochemistry IHC 57 HIF PH inhibitors 57 evaluating tivozanib 57 inhibit EGFR 57 prognostic indicators 57 masitinib 57 medically inoperable 57 qualitative serum 57 Loramyc R 57 SELDI TOF MS 57 transfection reagents 57 ResponseDX Colon ™ 57 CIN2 + 57 VerifyNow P#Y# 57 PLK1 SNALP 57 olaparib 57 anti CD3 57 decitabine 57 Sulonex TM 57 selective inhibition 57 antitumor effect 57 adjuvant GIST 57 NEVO ™ 57 HER2 ErbB2 57 AttoSense 57 Anticalins ® 57 Doxil ® 57 Hepatocellular Carcinoma HCC 57 vivo potency 57 TLR9 agonists 57 biomarkers 57 rNAPc2 57 oral taxane 57 Myocet 57 farletuzumab 57 MDV# 57 multiplex assay 57 metaglidasen 57 Epidermal Growth Factor Receptor 57 eTag 57 Delcath PHP System 57 gene expression profiling 57 Zemiva TM Trofex TM 57 Modrenal 57 investigational therapies 57 cediranib 57 HRPC 57 differentiated thyroid 57 sapacitabine 57 entinostat 57 EGFR mutation status 57 rxRNA 57 CBLC# 57 PLAC test 57 Epi proColon 57 HDL Selective Delipidation 57 progesterone receptor PR 57 AQ4N 57 Amigal 57 Gemzar ® 57 A3 adenosine receptor 57 TRIOLEX 57 fine needle aspiration 57 MetaDrug TM 57 PDX pralatrexate 57 PIK3CA 57 NPC 1C 57 Pharmacodynamic 57 refractory chronic lymphocytic 57 metastatic RCC 57 pegylated interferons 56 miRview ® 56 P2V TM 56 ADVEXIN therapy 56 Lp PLA 2 56 oral FTY# 56 CINtec R 56 antiangiogenic therapy 56 fluoropyrimidine 56 multiplex PCR 56 Orazol 56 Immunohistochemistry IHC 56 PI3K/Akt pathway inhibitor 56 Carfilzomib 56 pharmacological chaperone 56 KRAS BRAF 56 pharmacodynamic parameters 56 BladderChek Test 56 R sorafenib tablets 56 MammaPrint ® 56 biologic therapeutics 56 biomarker assay 56 HCD# [002] 56 ENRICH trial 56 TroVax ® 56 vascular disrupting agents 56 metabolite identification 56 sarcosine 56 TELINTRA 56 Anticalins R 56 PRT# 56 Romidepsin 56 bevacizumab Avastin ® 56 Panzem 56 promoter methylation 56 ZADAXIN 56 HER2 gene 56 SIR Spheres 56 Tumorgraft 56 CGEN # 56 vitro ADME 56 ErbB2 positive 56 Immunotherapeutic 56 HER2 positive cancers 56 HGS# 56 ApoB SNALP 56 Pharmacogenetic 56 CAMPATH 56 GeneChip ® 56 ONCONASE R 56 antibody MAb 56 custirsen 56 imetelstat 56 CytoCore Solutions 56 antagomirs 56 sensitivity specificity 56 ResponseDX Colon TM 56 ResponseDX Lung ™ 56 DPX Survivac 56 PRTX 56 MTWA 56 IMiDs 56 ZFP TF 56 neoadjuvant 56 velafermin 56 TLR antagonists 56 ON #.Na 56 Dicer Substrate Technology 56 Selective Electrochemical Tumor Ablation 56 galiximab 56 PRECISE trial 56 whose tumors overexpress 56 tesmilifene 56 AdnaTest 56 FLT3 56 Xcellerated T Cells 56 follicular lymphomas 56 PROCHYMAL 56 Amplimexon 56 Radient Pharmaceutical current 56 anticancer agent 56 Proxinium TM 56 Azixa 56 LHRH antagonists 56 relapsed SCLC 56 trastuzumab Herceptin R 56 CINtec ® PLUS 56 FOLFOX6 chemotherapy regimen 56 iChemVELOCITY 56 FOLOTYN ® 56 ponatinib 56 AGHD 56 HER2 negative 56 PNH patients 56 GAP #B# 56 interferon gamma 1b 56 riociguat 56 HeliScope Sequencer 56 PROGENSA R 56 Onko Sure TM 56 personalized immunotherapy 56 CINTREDEKIN BESUDOTOX 56 JNJ Q2 56 OHR/AVR# 56 COMT inhibitors 56 microRNA profiling 56 DNA methylation biomarker 56 Bafetinib 56 chemosensitivity 56 IRESSA 56 Ixempra 56 vitro assay 56 UVIDEM 56 axitinib 56 AtherOx 56 DNA methylation markers 56 oncologic outcomes 56 Electronic Brachytherapy 56 BioMAP ® Systems 56 Chronix 56 BiTE antibodies targeting 56 HyACT 56 Digene HPV Test 56 NEUMUNE 56 microRNA expression 56 SureSelect 56 StemEx R 56 Fc gamma receptors 56 Chimigen TM 56 proteasome inhibitor 56 TLK# 56 PNP inhibitor 56 cobas HPV Test 56 sargramostim 56 Ampligen ® 56 Cardiotoxicity 56 elacytarabine 56 ALN HPN 56 EAA TM 56 NEUGENE 56 Aurexis 56 immunochemical 56 CRLX# 56 investigational humanized monoclonal antibody 56 MCSP respectively 56 encapsulates siRNAs 56 Gastrointestinal Stromal Tumors 56 Gliadel Wafer 56 pharmacodynamic 56 GSTP1 56 GenPath 56 Glufosfamide 56 ocular formulation 56 therapeutic regimens 56 pancreatic adenocarcinoma 56 NGX# 56 Applied Biosystems TaqMan 56 hypoxic tumors 56 PKCi 56 Affymetrix GeneChip ® 56 R#/MEM # 56 potency selectivity 56 BCR ABL inhibitors 56 AlloMap 56 Alocrest 56 PREVU x 56 AdnaGen 56 Co Receptor Tropism 56 Zybrestat 56 AzaSite Plus 56 anticancer therapies 56 flavopiridol 56 Vaxfectin R adjuvant 56 OMP #M# 56 pharmacogenomic 56 squamous cell lung cancer 56 CYCLOSET 56 GRN#L 56 LE DT 56 LY# [003] 56 Solazed 56 EP #R 56 registrational 56 ColoMarker 56 BiTE antibody 56 diagnostic biomarkers 56 ULTRIO 56 RGB # 56 Zolinza 56 Imprime PGG 56 endoglin 56 FavId 56 HuMax CD4 56 predictive toxicology 55 EndoTAGTM 1 55 EOquin TM 55 Her2/neu 55 XL# XL# 55 Generx TM 55 DNA methyltransferases 55 FCGR3A 55 Fludara 55 tivozanib 55 Deforolimus 55 MabCampath 55 Taxotere ® 55 PSADT 55 JAK2 inhibitors 55 Flow cytometry 55 Oncotype DX TM 55 COLARIS 55 radiolabeled TM# 55 Prognostic Value 55 iroxanadine 55 AppyScore 55 prognostic biomarker 55 Intravenous CP 55 file INDs 55 unresectable tumors 55 whole genome genotyping 55 oral prodrug 55 stratify patients 55 INCB# [003] 55 Phase #b/#a trial 55 molecularly targeted 55 SNP Genotyping 55 multitargeted 55 Phase Ib II 55 tumor hypoxia 55 Surfaxin LS 55 ovarian pancreatic 55 OvaRex MAb 55 mutational status 55 compound AEZS 55 diagnostic assays 55 relapsed MM 55 B7 H3 55 pharmacokinetic PK 55 IDH1 55 Ibis T# 55 Leukine ® 55 Trastuzumab Herceptin 55 tiapamil 55 Pharmacokinetic PK 55 Estrogen Receptor 55 TNFerade 55 INCB# [002] 55 heparanase 55 cisplatin resistant 55 EndoTAG TM -1 55 CRMD# 55 Cervista HPV 55 antiviral therapies 55 ONTAK 55 Cerashield 55 EGFR inhibitors 55 multiplexed assays 55 relapsed MCL 55 Xeloda ® 55 tezampanel 55 lesinurad 55 NADiA TM 55 DNA methylation patterns 55 huN# DM1 55 echocardiographic parameters 55 mutational analysis 55 perifosine 55 KIF6 55 NPRL2 55 MGN# 55 rEEG 55 histological subtypes 55 Octreolin 55 PEG PAL 55 ESBA# 55 genotyping assay 55 Affymetrix microarray technology 55 mapatumumab 55 RQ PCR 55 atherosclerosis regression 55 small molecule defensin 55 monoclonal antibody therapies 55 INC# 55 RainStorm 55 poly ADP ribose polymerase 55 pradefovir 55 prognostic 55 cintredekin besudotox 55 MALDI-TOF/TOF 55 metastatic neuroendocrine tumors 55 EGS# 55 PD2i R 55 SmartChip 55 PROactive study 55 chemotherapeutic drug 55 GVAX ® 55 Trofile TM 55 mifamurtide 55 Azedra TM Onalta TM 55 tumorigenicity 55 untreated metastatic melanoma 55 PARP inhibition 55 TELCYTA 55 Circulating Tumor Cells 55 Curaxin 55 recurrent GBM 55 humanized anti 55 microarray analysis 55 ixabepilone 55 kinase profiling 55 MAb 55 eTag assay 55 LungAlert TM 55 G#DT 55 Bicifadine 55 Factor Receptor 55 Bionate ® PCU 55 BiovaxID 55 otelixizumab 55 hyaluronidase enzyme 55 MEK inhibitor RDEA# 55 Pharmacokinetic parameters 55 ADME Tox 55 BiTE 55 Cytolin R 55 Pulmotype 55 biomarker validation 55 Cardio3KG 55 AZILECT ® 55 modified glutathione analog 55 risk stratification 55 Exelixis XL# 55 TPI ASM8 55 xMAP technology 55 T DM1 55 acid phosphatase PAP 55 druggable targets 55 hormone deprivation 55 pediatric malignancies 55 HER1 55 optimal dosing regimens 55 TIMP 1 55 lactate dehydrogenase LDH 55 radiation sensitizer 55 ISF# 55 phase IIa clinical 55 metabolomics driven 55 AzaSite Xtra 55 urine cytology 55 RenalGuard Therapy 55 tyrosine kinase inhibitors 55 TriGrid 55 T SPOT.TB 55 Abiraterone acetate 55 myelofibrosis polycythemia vera 55 micrometastases 55 Li Fraumeni 55 Renal Cell Carcinoma RCC 55 genomic proteomic 55 Phase #b/#a clinical 55 histologic subtypes 55 UltiMAb ® 55 quantitative proteomics 55 NimbleGen arrays 55 Etubics 55 triphendiol 55 DNAwithPap TM Test 55 endothelin antagonists 55 Digital Mammographic Imaging 55 molecular markers 55 thalidomide Thalomid 55 Secondary efficacy endpoints 55 MORAb 55 BRAF mutation 55 Aplidin 55 agonistic human 55 5 Fluorouracil 55 Sandostatin LAR Depot 55 clinicopathological features 55 silico prediction 55 peptide antigens 55 PET tracers 55 ISIS # 55 anti angiogenic therapy 55 BioMAP ® 55 talabostat 55 seliciclib 55 ChemoFx ® 55 GKAs 55 Poly ICLC 55 breast carcinoma 55 Ixabepilone 55 Androxal 55 telomerase therapeutic 55 PKC# 55 SILAC 55 BRACAnalysis ® 55 orthotopic model 55 GRNVAC1 55 endophenotypes 55 genomic profiling 55 QPCR 55 bendamustine HCl 55 Immunohistochemistry 55 AP# [003] 55 MiCK assay 55 Biomerk Tumorgraft 55 GAMMAGARD LIQUID 55 miRNA biomarkers 55 OvaDx 55 Squamous 55 BrachySil 55 hematological cancers 55 MAbs targeting 55 XL# XL# XL# XL# 55 Gefitinib 55 immatics 55 gene amplification 55 mTOR inhibitors 55 kinase inhibition 55 ResponseDX ™ 55 orally administered inhibitor 55 evaluating satraplatin 55 ADME properties 55 CXCR7 55 PD2i 55 oncolytic viruses 55 Haptoglobin 55 NMP# R 55 fulvestrant 55 intranasal delivery 55 EXPAREL ™ 54 bovine thrombin 54 NSCLC tumors 54 prognostic biomarkers 54 mechanistic insights 54 noninvasive prenatal tests 54 BACcel 54 Microvolt T Wave Alternans 54 phase IIb clinical 54 epothilone 54 PSP# [002] 54 miRs 54 targeted radiotherapeutic 54 PD2i ® nonlinear algorithm 54 Gamma Imaging BSGI 54 haematologic 54 tyrosine kinase inhibitor 54 Kerastick 54 FDG-PET/CT 54 cellular immunotherapy 54 enzyme immunoassay EIA 54 cardiac troponin T 54 protein biomarkers 54 L MTP PE 54 Tr DNA 54 GRN# 54 mSEPT9 biomarker 54 skin sterol 54 ColonSentry TM 54 hyperthermia therapy 54 SCIB1 54 adjuvant therapies 54 immunohistochemistry 54 Onko Sure ® 54 #beta HSD1 54 CyPath ® assay 54 Epothilones 54 cystatin C 54 ACTEMRA TM 54 APTIMA Combo 2 54 serum antibody 54 Poly ICR 54 accumulate preferentially 54 radiotherapeutic 54 nCounter 54 Aurora kinase 54 VerifyNow System 54 BHT DNA 54 ColonSentry ™ 54 neoadjuvant treatment 54 tests miRview TM 54 anticancer compound 54 Peptidomics 54 PrevOnco ™ 54 ZFP Therapeutics 54 Squalamine 54 CCX# B 54 microRNA diagnostic 54 quantitative RT PCR 54 Vaxfectin 54 cervical breast 54 OMAPRO ™ 54 picoplatin 54 Onalta TM 54 S. maltophilia 54 engineered RAP peptides 54 miR #a [001] 54 myeloproliferative disorders 54 anticoagulant reversing agent 54 bevacizumab Avastin